Clinical Trials

Clinical trials are specifically designed to assess the safety and effectiveness of new treatments, devices or existing treatments. Not all patients in a trial will receive the innovative treatment; some trials compare existing treatments. These studies involve human subjects, participants, who can enroll on a completely voluntary basis. Participants must sign a consent that outlines the details of the study. At that point, participants may ask the study staff questions pertaining to the trial.

While everyone has the right to apply for participation in the clinical research study, not everyone who applies will be able to proceed. Each clinical protocol has guidelines that help determine if a participant meets those qualifications. Because you are a volunteer, you may choose to leave the study at any point. Community Health Network has an Institutional Review Board that approves and monitors the studies to ensure patient safety.

Learn more at

Contact Us

To report a concern or learn more about clinical trials at Community, email or call 317-621-3840.

Meet the Research Teams Meet the Investigators

Current Trials

As a patient or family member you may be interested in participating in research trials that compare the effectiveness of treatment approaches to your condition. Explore current trials below in cancer care, heart and vascular, behavioral health and orthopedics.

Cancer Clinical Trials


A Randomized Phase III Trial of Memantine and Whole Brain Radiotherapy with or without Hippocampal Avoidance in Patients with Brain Metastases
Principal Investigator: Daniel Weed, MD


MonarchE: I3Y-MC-JPCF
A Randomized, Open-Label, Phase 3 study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative Breast Cancer
Principal Investigator: Annette Moore, MD

Breast Cancer Collaborative Registry
Principal Investigator: Anuj Agarwala, MD

A Randomized Phase III trial Comparing Axillary Lymph Node Dissection To Axillary Radiation In Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Principal Investigator: Timothy Goedde, MD

Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Principal Investigator: Shih Jack Wei, MD

A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer
Principal Investigator: Radhika Walling, MD

Feasibility Study of Motility Contrast Tomography for Predicting Therapeutic Response Among Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
Principal Investigator: Timothy Goedde, MD


Forward One
A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab soravtansine (IMGN853) Versus Investigator’s Choice of Chemotherapy in Women with Folate Receptor α-positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer (Method)

Head and Neck

RTOG 0920
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Principal Investigator: Shih Jack Wei, MD


informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia
Principal Investigator: Radhika Walling, MD

Myelofibrosis Observational Registry
Principal Investigator: Mary L. Mayer, MD


A Phase II single-arm trial to investigate tepotinib in stage IIIB/IV adenocarcinoma of the lung with MET exon 14 (METex14) skipping alterations after failure of at least one prior active therapy, including a platinum-doublet-containing regimen
Principal Investigator: Radhika Walling, MD

Randomized phase II trial of docetaxel plus nivolumab or docetaxel alone in patients with advanced non-squamous NSCLC and previous clinical benefit on treatment with single agent nivolumab
Principal Investigator: Radhika Walling, MD

Multiple Disease Sites

Molecular Analysis for Therapy Choice (MATCH)
Principal Investigator: Radhika Walling, MD

Urinary System

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer
Principal Investigator: Radhika Walling, MD

Phase Ib/II Study of Neoadjuvant Pembrolizumab (MK-3475) with Gemcitabine-Cisplatin (cisplatin eligible) or Gemcitabine (cisplatin-ineligible) in Subjects with T2-4aN0M0 Urothelial Cancer
Principal Investigator: Radhika Walling, MD

Heart and Vascular Clinical Trials

Coronary Artery Disease

A randomized, double-blind, placebo-controlled, event driven trial of weekly low dose methotrexate (LDM) in the prevention of cardiovascular events among stable coronary artery disease patients with type 2 diabetes or metabolic syndrome
Principal InvestigatorDeovrat Singh, MD

Heart Failure

A double blind randomized placebo controlled multicenter study to assess the efficacy and safety of omecamtiv mecarbil on mortality and morbidity in subjects with chronic heart failure with reduced ejection fraction
Principal Investigator: Bradley Weinberg, MD


Lomitapide Observational Worldwide Evaluation Registry
Principal Investigator: Jennifer Davel, MD

Percutaneous Coronary Intervention (PCI)

A prospective, multicenter single-arm study designed to assess the safety of 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention with the SynergyTM Everolimus Eluting Platinum Chromium Coronary Stent System
Principal Investigator: Sandeep Dube, MD

Pulmonary Hypertension

Open label extension study of inhaled treprostinil in subjects with pulmonary hypertension due to parenchymal lung disease

A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pulmonary hypertension due to parenchymal lung disease

Shelbourne Knee Center Research Studies

ACL Reconstruction

Objective and Subjective Outcomes after Anterior Cruciate Ligament Reconstruction
Principal Investigator: Donald Shelbourne, MD

Total Knee Arthroplasty

Factors Associated with Long-Term Success after Total Knee Arthroplasty
Principal Investigator: Rodney Benner, MD

Knee Arthroscopy

Subjective Follow-up of Patients who have Undergone Knee Arthroscopy
Principal Investigator: Donald Shelbourne, MD

Knee Osteoarthritis

Rehabilitation for Patients with Knee Osteoarthritis
Principal Investigator: Donald Shelbourne, MD

Patellofemoral Realignment Surgery

Objective and Subjective Outcomes after Patellofemoral Realignment Surgery
Principal Investigator: Donald Shelbourne, MD

Posterior Cruciate Ligament Injury

Natural History of Acute, Isolated, Nonoperatively Treated Posterior Cruciate Ligament Injuries
Principal Investigator: Donald Shelbourne, MD

Recalcitrant Patellar Tendinosis

Recalcitrant Patellar Tendinosis: Objective and Functional Outcomes
Principal Investigator: Donald Shelbourne, MD